Clinical Trials Browser

INDUSTRY × pasireotide × Endocrine × Clear all

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Follicular

NCT03972488 2026-01-21

NETTER-2

Phase 3 Active not recruiting

226 enrolled 14 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Phase 4 Completed

337 enrolled 8 charts

DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT01563354 2021-04-02

LUNA

Phase 2 Completed

124 enrolled 18 charts

Endocrine

Carcinoma, Neuroendocrine

NCT01364415 2020-12-21

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

Phase 1 Completed

29 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT01915303 2020-09-18

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Phase 2 Terminated

68 enrolled 25 charts

Endocrine

Adrenocortical Hyperfunction, Pituitary Neoplasms, Pituitary ACTH Hypersecretion

NCT01673646 2019-09-16

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Phase 2 Completed

33 enrolled 24 charts

Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT00958841 2016-07-26

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Phase 2 Terminated

118 enrolled 11 charts

EndocrineGastrointestinal

ACTH Syndrome, Ectopic, Nelson Syndrome, Pancreatic Neoplasms, Pituitary Neoplasms, Neuroectodermal Tumors, Primitive

NCT00088595 2012-06-04

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

Phase 2 Completed

45 enrolled 10 charts

Endocrine

Carcinoid Tumor, Serotonin Syndrome

Clinical Trials

NETTER-3

NETTER-2

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

LUNA

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors